Tenofovir disoproxil has one of the largest evidence bases of any medicine used in sexual health, spanning HIV treatment, HIV prevention and hepatitis B, across more than two decades of trials and real-world follow-up.
What established it as treatment?
Registration studies in the early 2000s showed tenofovir-based combinations achieving durable viral suppression with better tolerability than the thymidine analogues then in use, which caused fat loss and mitochondrial problems. Guidelines moved towards it steadily, and tenofovir with emtricitabine became the standard nucleoside backbone for many years.
What did the iPrEx study show?
iPrEx was the first large trial of oral PrEP in men who have sex with men and transgender women. Overall it found a substantial reduction in HIV acquisition, and the more informative finding came from analysing drug levels: among participants with detectable drug in their blood, protection was far higher than the headline figure suggested.
Why did that matter?
Because it demonstrated that the headline number reflected adherence rather than the drug's capability. Later studies were designed around that insight, and it is the reason clinicians emphasise taking PrEP consistently rather than treating the overall trial figure as the expected protection.
What did PROUD find?
PROUD was conducted in UK sexual health clinics and compared immediate PrEP with deferred PrEP among men at high risk. The reduction in new infections was so large that the deferred arm was offered PrEP early on ethical grounds. It is the study most directly relevant to UK practice.
What did IPERGAY establish?
IPERGAY tested event-based dosing rather than daily, using a double dose before sex and two further doses afterwards. It found a large reduction in infections, establishing that on-demand dosing works for anal sex. This evidence applies to anal sex specifically and has not been established for vaginal or frontal sex.
Why the difference between sites?
Pharmacological studies measuring drug concentrations found that tenofovir reaches protective levels in rectal tissue considerably faster than in vaginal tissue, where around seven days of daily dosing is needed. That tissue difference, rather than anything about the people involved, is why the dosing advice differs.
What does the long-term safety data show?
Large cohorts have tracked kidney function and bone density over years. Both show small average declines that are clinically insignificant for most people and matter for a minority, particularly those with existing kidney disease or other risk factors. Serious kidney injury is uncommon and is the main reason monitoring exists.
What about resistance?
Resistance emerging on PrEP is rare and occurs almost entirely where someone starts PrEP with an undiagnosed recent infection. This is the reason for testing before starting and at every review, and it is why a recent possible exposure should be mentioned rather than glossed over.
What about hepatitis B?
Trials in chronic hepatitis B showed durable viral suppression with very low rates of resistance over years of treatment, which is better than the older drugs used for that condition. This is why tenofovir is preferred where someone has both infections.
What is the overall picture?
Consistent and unusually robust. Effectiveness in both prevention and treatment is well established, the failure modes are understood, and the safety concerns are known, quantified and monitored rather than speculative.
How does real-world data compare with trials?
Broadly consistent. Large programmes in the UK and elsewhere have reported very low rates of HIV acquisition among people taking PrEP as prescribed, matching what the trials predicted. Where infections occur, they overwhelmingly involve gaps in taking it rather than the drug failing.
Is the evidence still developing?
Less so for effectiveness, which is settled, and more for long-term safety in people taking it for decades. Cohorts are now following people for twenty years and more, and the picture has not changed substantially from what the earlier data suggested.
Where can you read the evidence yourself?
NAM aidsmap summarises HIV research reliably and without overstatement, and the British HIV Association publishes the guidelines UK clinicians actually follow. Both are freely available and are considerably more useful than a general search, which tends to surface material from other countries with different practice.